GLI-2 Antibody (Mouse mAb) [H16L16]

Application: Reactivity: Mouse, Human, Rat

Usage Information

Dilution
WB1:100- 1:1000 IP1:200-1:400 IHC1:50-1:500 IF1:50-1:500

Application
WB, IP, IHC, IF, ELISA

Reactivity
Mouse, Human, Rat

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
168 kDa

Datasheet & SDS

Biological Description

Specificity
GLI-2 Antibody (Mouse mAb) [H16L16] detects endogenous levels of total GLI-2 protein.

Clone
H16L16

Synonym(s)
GLI2

Background
GLI2 is a zinc finger transcription factor of the GLI family that functions as a principal effector of Sonic Hedgehog (Shh) signaling, integrating pathway activity into context‑dependent transcriptional programs during embryonic patterning and in disease. The protein contains an N‑terminal regulatory region with repressor elements, a central Krüppel‑like zinc finger DNA‑binding domain that recognizes GLI consensus motifs in target promoters and enhancers, and a C‑terminal transactivation region whose activity is controlled by multisite phosphorylation and proteasome‑dependent processing. In the absence of Hedgehog ligands, protein kinase A together with casein kinase 1 and GSK3 phosphorylates clusters of serines in the C‑terminal region of GLI2, creating binding sites for the SCF–βTrCP ubiquitin ligase; this promotes partial proteolysis that yields a shorter GLI2 repressor species and also drives full‑length GLI2 degradation, keeping activator levels low and limiting expression of Hedgehog target genes. Hedgehog pathway activation prevents this phosphorylation cascade, stabilizes full‑length GLI2, and allows its nuclear accumulation as a transcriptional activator, where it up‑regulates canonical Hedgehog targets involved in proliferation, fate specification, and tissue morphogenesis; DYRK2‑dependent phosphorylation at conserved sites downstream of Smoothened provides an additional positive input that enhances GLI2 activator function in specific developmental contexts such as skeletal formation, establishing a stepwise activation scheme that combines relief of PKA‑mediated inhibition with DYRK2‑mediated stimulatory phosphorylation. Gli2 is required for proper development of the ventral neural tube, hair follicles, and thalamocortical projections, and its role is only partially redundant with that of Gli3, which is more strongly biased toward repressor function, highlighting GLI2 as the dominant activator in many vertebrate Hedgehog responses. Human GLI2 loss‑of‑function variants are associated with holoprosencephaly spectrum and related midline defects, often with pituitary and craniofacial anomalies, consistent with impaired Shh–GLI2 signaling during forebrain and facial development, while elevated GLI2 activity driven by ligand‑dependent or noncanonical inputs (including TGF‑β/SMAD signaling) contributes to the proliferative and invasive behavior of several cancers, such as basal cell carcinoma and oral squamous cell carcinoma. GLI2 operates as a finely tuned transcriptional switch whose activity is dictated by a combinatorial phosphorylation “code” and regulated by proteolysis, linking upstream Hedgehog and cooperating pathways to gene networks that govern proliferation, patterning, and tumor progression.

Background

GLI2 is a zinc finger transcription factor of the GLI family that functions as a principal effector of Sonic Hedgehog (Shh) signaling, integrating pathway activity into context‑dependent transcriptional programs during embryonic patterning and in disease. The protein contains an N‑terminal regulatory region with repressor elements, a central Krüppel‑like zinc finger DNA‑binding domain that recognizes GLI consensus motifs in target promoters and enhancers, and a C‑terminal transactivation region whose activity is controlled by multisite phosphorylation and proteasome‑dependent processing. In the absence of Hedgehog ligands, protein kinase A together with casein kinase 1 and GSK3 phosphorylates clusters of serines in the C‑terminal region of GLI2, creating binding sites for the SCF–βTrCP ubiquitin ligase; this promotes partial proteolysis that yields a shorter GLI2 repressor species and also drives full‑length GLI2 degradation, keeping activator levels low and limiting expression of Hedgehog target genes. Hedgehog pathway activation prevents this phosphorylation cascade, stabilizes full‑length GLI2, and allows its nuclear accumulation as a transcriptional activator, where it up‑regulates canonical Hedgehog targets involved in proliferation, fate specification, and tissue morphogenesis; DYRK2‑dependent phosphorylation at conserved sites downstream of Smoothened provides an additional positive input that enhances GLI2 activator function in specific developmental contexts such as skeletal formation, establishing a stepwise activation scheme that combines relief of PKA‑mediated inhibition with DYRK2‑mediated stimulatory phosphorylation. Gli2 is required for proper development of the ventral neural tube, hair follicles, and thalamocortical projections, and its role is only partially redundant with that of Gli3, which is more strongly biased toward repressor function, highlighting GLI2 as the dominant activator in many vertebrate Hedgehog responses. Human GLI2 loss‑of‑function variants are associated with holoprosencephaly spectrum and related midline defects, often with pituitary and craniofacial anomalies, consistent with impaired Shh–GLI2 signaling during forebrain and facial development, while elevated GLI2 activity driven by ligand‑dependent or noncanonical inputs (including TGF‑β/SMAD signaling) contributes to the proliferative and invasive behavior of several cancers, such as basal cell carcinoma and oral squamous cell carcinoma. GLI2 operates as a finely tuned transcriptional switch whose activity is dictated by a combinatorial phosphorylation “code” and regulated by proteolysis, linking upstream Hedgehog and cooperating pathways to gene networks that govern proliferation, patterning, and tumor progression.

References
https://pubmed.ncbi.nlm.nih.gov/16611981/ https://pubmed.ncbi.nlm.nih.gov/34298625/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%